Vyne Therapeutics

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded on October 21, and is headquartered in Bridgewater, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Bridgewater, NJ.

Vyne Therapeutics is executing well, successfully launching 2 differentiated dermatology products this year.

Vyne Therapeutics: Strong Execution And Potential Upside From Strategic Options

BRIDGEWATER, N.J., Oct. 7, 2020 /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced a coverage update for its novel ZILXI™ (minocycline) topical foam, 1.5%. ZILXI is the first minocycline product of any form to be FDA approved for use in rosacea...

VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts

BRIDGEWATER, N.J., Oct. 1, 2020 /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that its novel ZILXI™ (minocycline) topical foam, 1.5% will be available on October 1, 2020 by prescription for the treatment of inflammatory lesions of rosacea...

VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1st

ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults

VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% is Available in Pharmacies Nationwide Today, October 1st

Since the time of my last article, Vyne's market cap has dropped from $330 million to just $285 million.

VYNE's Current Market Cap Presents An Attractive Opportunity

Live webinar on October 1st to feature presentations by 3 KOLs in dermatology Live webinar on October 1st to feature presentations by 3 KOLs in dermatology

VYNE Therapeutics to Host Physician Symposium on AMZEEQ® and ZILXI™

BRIDGEWATER, N.J., Sept.  14, 2020  (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the Board of Directors of the Company appointed Mr. Patrick G. LePore to serve as a director of the Company, effective as of September 10, 2020.

VYNE Therapeutics Announces the Appointment of  Patrick G. LePore to its Board of Directors

News for Vyne Therapeutics Stock (VYNE)